Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System
- PMID: 1928197
- DOI: 10.1016/0002-9343(91)90349-3
Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System
Abstract
More than 25,000 primary bloodstream infections (BSIs) were identified by 124 National Nosocomial Infections Surveillance System hospitals performing hospital-wide surveillance during the 10-year period 1980-1989. These hospitals reported 6,729 hospital-months of data, during which time approximately 9 million patients were discharged. BSI rates by hospital stratum (based on bed size and teaching affiliation) and pathogen groups were calculated. In 1989, the overall BSI rates for small (less than 200 beds) nonteaching, large nonteaching, small (less than 500 beds) teaching, and large teaching hospitals were 1.3, 2.5, 3.8, and 6.5 BSIs per 1,000 discharges, respectively. Over the period 1980-1989, significant increases (p less than 0.0001) were observed within each hospital stratum, in the overall BSI rate and the BSI rate due to each of the following pathogen groups: coagulase-negative staphylococci, Staphylococcus aureus, enterococci, and Candida species. In contrast, the BSI rate due to gram-negative bacilli remained stable over the decade, in all strata. Except for small nonteaching hospitals, the greatest increase in BSI rates was observed in coagulase-negative staphylococci (the percentage increase ranged between 424% and 754%), followed by Candida species (219-487%). In small nonteaching hospitals, the greatest increase was for S. aureus (283%), followed by enterococci (169%) and coagulase-negative staphylococci (161%). Our analysis documents the emergence over the last decade of coagulase-negative staphylococci as one of the most frequently occurring pathogens in BSI.
Similar articles
-
Nosocomial infections in combined medical-surgical intensive care units in the United States.Infect Control Hosp Epidemiol. 2000 Aug;21(8):510-5. doi: 10.1086/501795. Infect Control Hosp Epidemiol. 2000. PMID: 10968716
-
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.Clin Infect Dis. 2004 Aug 1;39(3):309-17. doi: 10.1086/421946. Epub 2004 Jul 15. Clin Infect Dis. 2004. PMID: 15306996
-
Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007.JAMA. 2009 Feb 18;301(7):727-36. doi: 10.1001/jama.2009.153. JAMA. 2009. PMID: 19224749
-
Gram-negative bloodstream infections.Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S10-4. doi: 10.1016/j.ijantimicag.2008.06.015. Epub 2008 Sep 4. Int J Antimicrob Agents. 2008. PMID: 18775648 Review.
-
Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections.Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S357-70. doi: 10.1093/clinids/7.supplement_3.s357. Rev Infect Dis. 1985. PMID: 3901203 Review.
Cited by
-
Brazilian Sepsis Epidemiological Study (BASES study).Crit Care. 2004 Aug;8(4):R251-60. doi: 10.1186/cc2892. Epub 2004 Jun 15. Crit Care. 2004. PMID: 15312226 Free PMC article.
-
Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia.Antimicrob Agents Chemother. 2006 Mar;50(3):994-1000. doi: 10.1128/AAC.50.3.994-1000.2006. Antimicrob Agents Chemother. 2006. PMID: 16495262 Free PMC article.
-
Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers.J Clin Microbiol. 2006 Aug;44(8):2816-23. doi: 10.1128/JCM.00773-06. J Clin Microbiol. 2006. PMID: 16891497 Free PMC article.
-
Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule.Appl Environ Microbiol. 2002 Nov;68(11):5459-63. doi: 10.1128/AEM.68.11.5459-5463.2002. Appl Environ Microbiol. 2002. PMID: 12406738 Free PMC article.
-
Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):10-6. doi: 10.1046/j.1365-2125.2003.01993.x. Br J Clin Pharmacol. 2003. PMID: 14616408 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Other Literature Sources